Portal de Periódicos da CAPES

Effectiveness of guselkumab in patients with facial and/or genital psoriasis: Interim analysis results at Week 12 from the GULLIVER study

2024; Wiley; Linguagem: Inglês

10.1111/jdv.20187

1468-3083

Claudio Bonifati, Serena Lembo, Antonio Giovanni Richetta, Marco Romanelli, Francesca Satolli, Monica Corazza, Laura Atzori, Claudia Lasagni, Concetta Potenza, Paola Savoia, Federico Bardazzi, Vito Di Lernia, Luca Bianchi, Gabriella Fabbrocini, Claudia Giofrè, Leonardo Zichichi, Claudio Guarneri, Sabatino Pallotta, Maria Concetta Fargnoli, Francesco Loconsole, Annamaria Offidani, Martina Burlando, Stefano Piaserico, Ketty Peris, Manuela Papini, Carlo Giovanni Carrera, Antonio Costanzo, Francesca Prignano, Maria Rita Bongiorno, Paolo Dapavo, Luca Stingeni, Massimo Donini, Giuseppe Micali, Franco Rongioletti, Giuseppe Stinco, Talia Gramiccia, Giulia Cantini, Giuseppe Argenziano,

Asthma and respiratory diseases

Facial (FP) and genital psoriasis (GP) significantly affect patients' quality of life. Despite the advances in treatments, limited data on efficacy and safety are available on these difficult-to-treat areas. Guselkumab is an interleukin (IL)-23 inhibitor which has been proven effective in treating patients with moderate-to-severe plaque psoriasis.